UNCY
NASDAQ · Biotechnology
Unicycive Therapeutics Inc
$3.64
-0.14 (-3.70%)
Open$3.70
Previous Close$3.78
Day High$3.71
Day Low$3.56
52W High$8.74
52W Low$3.33
Volume—
Avg Volume1.01M
Market Cap100.59M
P/E Ratio—
EPS$-1.62
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+72.3% upside
Current
$3.64
$3.64
Target
$6.27
$6.27
$3.63
$6.27 avg
$7.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.90M | 51.72M | 45.87M |
| Net Income | -11,930,457 | -10,903,389 | -10,566,816 |
| Profit Margin | -22.6% | -21.1% | -23.0% |
| EBITDA | -19,602,786 | -19,995,313 | -16,713,067 |
| Free Cash Flow | -9,449,797 | -9,177,412 | -10,735,832 |
| Rev Growth | -5.2% | +18.0% | +24.4% |
| Debt/Equity | 0.52 | 0.63 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |